{"id":252,"date":"2025-06-11T13:52:30","date_gmt":"2025-06-11T13:52:30","guid":{"rendered":"https:\/\/analizesanocare.ro\/?post_type=product&#038;p=252"},"modified":"2025-08-08T13:56:57","modified_gmt":"2025-08-08T13:56:57","slug":"testare-genetica-pentru-controlul-greutatii-weight-sensor","status":"publish","type":"product","link":"https:\/\/analizesanocare.ro\/en\/analiz\u0103\/testare-genetica-pentru-controlul-greutatii-weight-sensor\/","title":{"rendered":"Testare genetica pentru controlul greutatii (Weight Sensor)"},"content":{"rendered":"<h2><strong>Informa\u021bii generale \u2013 Testare genetic\u0103 pentru controlul greut\u0103\u021bii (test de nutrigenetica) \u2013 (Weight Sensor)<\/strong><\/h2>\n<p>Potrivit Centrului pentru Controlul \u0219i Prevenirea Bolilor (CDC), \u00een ultimele dou\u0103 decenii s-a \u00eenregistrat o cre\u0219tere constant\u0103 a ratei obezit\u0103\u021bii \u00een Statele Unite \u00een r\u00e2ndul adul\u021bilor de la 19,4% \u00een 1997 la 24.5% \u00een 2004, 26.6% \u00een 2007, 33.8% \u00een 2008, 35.7% \u00een 2010. \u00cen perioada 2011-2014 prevalen\u021ba obezit\u0103\u021bii a fost de 36.5% la adul\u021bi \u0219i 17% la adolescen\u021bi (1).<\/p>\n<p>De asemenea, un raport recent al Organiza\u021biei Mondiale a S\u0103n\u0103t\u0103\u021bii (OMS) arat\u0103 c\u0103 \u00eentreaga Europ\u0103 va trebui s\u0103 fac\u0103 fa\u021b\u0103 epidemiei de obezitate, care va ajunge la cote alarmante \u00een anul 2030. Astfel, conform statisticilor OMS prevalen\u021ba mondial\u0103 a obezit\u0103\u021bii s-a triplat din 1975. \u00cen 2016 num\u0103rul total al adul\u021bilor supraponderali a dep\u0103\u0219it cifra de 1,9 miliarde (incluz\u00e2nd aici peste 350 milioane de persoane obeze), iar aproximativ 10% dintre copii au fost considera\u021bi supraponderali sau obezi.<\/p>\n<p>Epidemia mondial\u0103 de obezitate este cauzat\u0103 \u00een principal de factorii de mediu reprezenta\u021bi de consumul excesiv de alimente \u0219i lipsa activit\u0103\u021bii fizice. Obezitatea determin\u0103 apari\u021bia bolilor cardiovasculare, a <a href=\"https:\/\/www.synevo.ro\/diabetul-zaharat-tip-2\/\" data-wpel-link=\"internal\">diabetului zaharat de tip 2<\/a> sau a unor forme de cancer (aproximativ 25 -30% din cazurile de cancer de s\u00e2n, colon, endometru, rinichi \u0219i esofag) (2).<\/p>\n<p>\u00cen Rom\u00e2nia, conform studiului epidemiologic na\u021bional PREDATORR (Prevalen\u021ba Diabetului, Prediabetului, Supraponderii, Obezit\u0103\u021bii, Dislipidemiei, Hiperuricemiei \u0219i Bolii Cronice de Rinichi) ini\u021biat \u00een 2013, se \u00eenregistreaz\u0103 o prevalen\u021ba global\u0103 a obezit\u0103\u021bii, supraponderalit\u0103\u021bii, obezit\u0103\u021bii abdominale \u0219i a sindromului metabolic de 31.9%, 34.7%, 73.9% \u0219i respectiv 38.5% (3).<\/p>\n<p>Excesul de greutate \u0219i obezitatea se caracterizeaz\u0103 printr-o acumulare anormal\u0103 sau excesiv\u0103 de gr\u0103sime care duce la afectarea st\u0103rii de s\u0103n\u0103tate. OMS define\u0219te supraponderalitatea \u0219i obezitatea lu\u00e2nd \u00een considerare indicele de masa corporal\u0103 (BMI):<\/p>\n<ul>\n<li>supraponderalitatea: BMI \u2265 25 kg\/m2<\/li>\n<li><a href=\"https:\/\/www.synevo.ro\/obezitatea-problema-sanatate-a-lumii-moderne\/\" data-wpel-link=\"internal\">obezitatea<\/a>: BMI \u2265 30 kg\/m2.<\/li>\n<\/ul>\n<p>La copii se ia \u00een considerare v\u00e2rsta pentru definirea supraponderabilit\u0103\u021bii \u0219i obezit\u0103\u021bii (2).<\/p>\n<p>Patogenia obezit\u0103\u021bii este \u00een mod cert complex\u0103, implic\u00e2nd multiple interac\u021biuni \u00eentre factorii comportamentali, de mediu \u0219i genetici. Prevalen\u021ba cresc\u00e2nd\u0103 a obezit\u0103\u021bii poate fi par\u021bial atribuit\u0103 consumului excesiv de alimente \u0219i stilului de via\u021b\u0103 relativ sedentar al timpurilor moderne, \u00eens\u0103 studii relativ recente au ar\u0103tat c\u0103 factorii genetici influen\u021beaz\u0103 semnificativ riscul de a deveni obezi.<\/p>\n<p>Astfel, se estimeaz\u0103 c\u0103 \u223c30% \u2013 40% din varia\u021bia BMI poate fi atribuit\u0103 geneticii iar 60-70% mediului. Studiile efectuate pe gemeni, folosite ca model pentru a evalua componenta genetic\u0103 a obezit\u0103\u021bii, au ar\u0103tat o concordan\u021b\u0103 \u00een ceea ce prive\u0219te BMI de 70-90% pentru gemenii monozigoti si 35-45% pentru dizigoti (4).<\/p>\n<p>\u00centre nutri\u021bie \u0219i genomul uman exist\u0103 o rela\u021bie bidirec\u021bional\u0103 cee ce a condus la definirea unor entit\u0103\u021bi noi \u2013 nutrigenetica \u0219i nutrigenomica. Pe de o parte, <strong>nutrigenetica<\/strong> studiaz\u0103 modul \u00een care profilul genetic individual influen\u021beaz\u0103 r\u0103spunsul organismului la diferi\u021bii nutrien\u021bi din diet\u0103, iar pe de alt\u0103 parte, <strong>nutrigenomica<\/strong> analizeaz\u0103 efectele componentelor bioactive din alimente asupra expresiei genice (5).<\/p>\n<p>Testele de nutrigenetic\u0103 au drept scop stabilirea profilului genetic al unei persoane \u00een vederea instituirii unei diete personalizate care s\u0103 conduc\u0103 la sc\u0103derea \u00een greutate \u0219i s\u0103 \u00eembun\u0103t\u0103\u021beasc\u0103 starea de s\u0103n\u0103tate (6).<\/p>\n<p>Testul Weight sensor disponibil \u00een laboratoarele Synevo este un test de nutrigenetic\u0103 ce analizeaz\u0103 polimorfisme genetice ce au impact important \u00een apari\u021bia obezit\u0103\u021bii:<\/p>\n<ul>\n<li>FABP2 (rs1799883),<\/li>\n<li>PPARG (rs1801382),<\/li>\n<li>ADRB2 (rs1042713), ADRB2 (rs1042714), ADRB3 (rs4994),<\/li>\n<li>FTO (rs9939609),<\/li>\n<li>APOA2 (rs5082), APOA5 (rs662799)<\/li>\n<\/ul>\n<p><strong>FABP2 (rs1799883)<\/strong><\/p>\n<p>Proteina FABP2 (Fatty acid-binding protein 2) sau FABP intestinal (I-FABP) face parte din superfamilia proteinelor FABP (\u00eemp\u0103r\u021bite \u00een 3 categorii: hepatice, intestinale, cardiace). Gena FABP2 este localizat\u0103 pe cromozomul 4 (4q28-4q31) \u0219i este formata din 4 exoni care con\u021bin ~ 700 bp \u0219i 3 introni care con\u021bin ~ 2650 bp. Proteina FABP2 este compusa din 131 de resturi de aminoacizi \u0219i are un situs de legare cu afinitate mare pentru acizii gra\u0219i cu lan\u021b lung at\u00e2t saturati c\u00e2t \u0219i nesaturati, indic\u00e2nd faptul c\u0103 ar putea avea un rol cheie \u00een absorb\u021bia \u0219i transportul intracelular al acizilor gra\u0219i cu lan\u021b lung.<\/p>\n<p>Polimorfismul cel mai intens studiat \u00een gena FABP2 este p.Ala54Thr (rs1799883) care rezult\u0103 prin substitu\u021bia nucleotidic\u0103 a guaninei (G) cu adenozina (A). Proteina care con\u021bine treonin\u0103 (Thr) are o afinitate de dou\u0103 ori mai mare pentru acizii gra\u0219i cu lan\u021b lung dec\u00e2t proteina care con\u021bine alanin\u0103 (Ala). Prezen\u021ba polimorfismului Ala54Thr are ca efecte cre\u0219terea transportului de acizi gra\u0219i liberi \u00een celulele intestinale \u0219i sinteza postprandial\u0103 de trigliceride, ceea ce se asociaz\u0103 cu niveluri bazale crescute de leptin\u0103 \u0219i insulin\u0103, BMI crescut, depunere de gr\u0103sime \u00een regiunea abdominal\u0103 \u0219i obezitate.<\/p>\n<p>Studiile efectuate p\u00e2n\u0103 \u00een prezent au ar\u0103tat c\u0103 exist\u0103 o asociere a polimorfismului FABP2 Ala54Thr cu obezitatea, displipidemia, rezisten\u021ba la insulin\u0103 \u0219i diabetul zaharat de tip 2 \u00een diferite grupuri etnice (6,7,8).<\/p>\n<p>Subiec\u021bii supraponderali \u0219i obezi care prezint\u0103 polimorfismul FABP2 rs1799883 pot beneficia de o diet\u0103 cu un con\u021binut redus de carbohidra\u021bi, moderat de gr\u0103simi \u0219i adecvat de proteine (6).<\/p>\n<div>\n<table class=\"wp-block-table w-100\">\n<tbody>\n<tr>\n<td width=\"121\">Genotip FABP2<\/td>\n<td width=\"115\">Frecven\u021b\u0103 (%)<\/td>\n<td width=\"387\">Efecte<\/td>\n<\/tr>\n<tr>\n<td width=\"121\">G\/G<\/td>\n<td width=\"115\">42<\/td>\n<td width=\"387\">\u2013<\/td>\n<\/tr>\n<tr>\n<td width=\"121\">A\/G<\/td>\n<td width=\"115\">51<\/td>\n<td width=\"387\">Cre\u0219terea riscului de depozitare a gr\u0103similor \u00een jurul organelor<\/td>\n<\/tr>\n<tr>\n<td width=\"121\">A\/A<\/td>\n<td width=\"115\">7<\/td>\n<td width=\"387\">Cre\u0219terea riscului de depozitare a gr\u0103similor \u00een jurul organelor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&nbsp;<\/p>\n<p><strong>FTO <\/strong><strong>(rs9939609)<\/strong><\/p>\n<p>Gena FTO localizat\u0103 pe cromozomul 16 codific\u0103 proteina asociat\u0103 obezit\u0103\u021bii \u0219i masei adipoase (engl. Fat mass and obesity-associated protein). Deficitul complet de FTO la om este asociat cu un sindrom autosomal-recesiv letal care include retard de cre\u0219tere, malforma\u021bii multiple \u0219i deces prematur, indic\u00e2nd faptul c\u0103 FTO este esen\u021bial\u0103 pentru dezvoltarea normal\u0103 a sistemul nervos central \u0219i cardiovascular.<\/p>\n<p>Pierderea unei c\u00f3pii func\u021bionale a genei FTO nu a fost asociat\u0103 cu un fenotip specific, iar muta\u021biile heterozigote inactivatoare se \u00eent\u00e2lnesc at\u00e2t la normoponderali c\u00e2t \u0219i la subiec\u021bii obezi. Inactivarea complet\u0103 sau par\u021bial\u0103 a genei FTO la \u0219oareci protejeaz\u0103 de obezitate, \u00een timp ce supraexprimarea FTO m\u0103re\u0219te aportul de alimente \u0219i are ca rezultat obezitatea (9).<\/p>\n<p>Polimorfismul FTO (rs9939609 T&gt;A) a fost asociat cu un comportament impulsiv de alimenta\u021bie (bulimie nervoas\u0103, hiperfagie) (10).<\/p>\n<div>\n<table class=\"wp-block-table w-100\">\n<tbody>\n<tr>\n<td width=\"102\">Genotip FTO<\/td>\n<td width=\"106\">Frecven\u021b\u0103 (%)<\/td>\n<td width=\"416\">Efecte<\/td>\n<\/tr>\n<tr>\n<td width=\"102\">T\/T<\/td>\n<td width=\"106\">25<\/td>\n<td width=\"416\"><\/td>\n<\/tr>\n<tr>\n<td width=\"102\">T\/A<\/td>\n<td width=\"106\">57<\/td>\n<td width=\"416\">Predispozi\u021bia la obezitate (OR: 1.34)&nbsp;<\/p>\n<p>Tendin\u021ba de a m\u00e2nca mai multe gust\u0103ri<\/p>\n<p>Pierderea \u00een greutate se poate face eficient prin activit\u0103\u021bi fizice<\/td>\n<\/tr>\n<tr>\n<td width=\"102\">A\/A<\/td>\n<td width=\"106\">18<\/td>\n<td width=\"416\">Senza\u021bie mai puternic\u0103 de foame&nbsp;<\/p>\n<p>Tendin\u021ba de a m\u00e2nca mai multe gust\u0103ri<\/p>\n<p>Pierderea \u00een greutate se poate face eficient prin activit\u0103\u021bi fizice<\/p>\n<p>Predispozi\u021bia la obezitate (OR: 1.67)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&nbsp;<\/p>\n<p><strong>APOA2<\/strong><strong> (rs5082), APOA5 (rs662799)<\/strong><\/p>\n<p>Apolipoproteina A-II (apo A-II) este a doua cea mai abundent\u0103 protein\u0103 component\u0103 a lipoproteinelor cu densitate mare (HDL-C), reprezent\u00e2nd aproximativ 20% din con\u021binutul proteic total al HDL. De\u0219i unele studii au g\u0103sit o supraexprimare a APOA2 la subiec\u021bii hipertrigliceridemici, obezi \u0219i insulino-rezisten\u021bi, rolul s\u0103u la om este \u00eenc\u0103 controversat. Polimorfismul c.-492T&gt;C (rs5082) din promotorul genei APOA2 este unul dintre cele mai studiate, iar genotipul CC a fost asociat cu cre\u0219terea BMI, a circumferin\u021bei abdominale, a procentului de gr\u0103sime corporal\u0103, a consumului de alimente \u0219i a HDL-C \u00een diferite popula\u021bii, \u00een prezen\u021ba unei diete bogate \u00een acizi gra\u0219i satura\u021bi. (11,12).<\/p>\n<p>Apolipoproteina (apo) A5 este un modulator al homeostazei triacilglicerolilor (trigliceridelor, TG) din plasm\u0103. Este sintetizat\u0103 exclusiv \u00een ficat, iar concentra\u021biile sale \u00een circula\u021bie sunt extrem de sc\u0103zute. APO-A5 intensific\u0103 activitatea lipoprotein-lipazei \u0219i inhib\u0103 produc\u021bia de trigliceride. Polimorfismul APOA5 c.-1131T&gt;C (rs662799) se asociaz\u0103 cu o lipoliz\u0103 redus\u0103 \u0219i hipertrigliceridemie (13).<\/p>\n<div>\n<table class=\"wp-block-table w-100\">\n<tbody>\n<tr>\n<td width=\"134\">Genotip APOA2<\/td>\n<td width=\"111\">Frecven\u021b\u0103 (%)<\/td>\n<td width=\"378\">Efecte<\/td>\n<\/tr>\n<tr>\n<td width=\"134\">C\/C<\/td>\n<td width=\"111\">18<\/td>\n<td width=\"378\">Cre\u0219terea riscului de depozitare a gr\u0103similor \u00een jurul organelor&nbsp;<\/p>\n<p>Tendin\u021ba de a m\u00e2nca mai mult<\/p>\n<p>Predispozi\u021bia genetic\u0103 la obezitate (OR: 1.7)<\/td>\n<\/tr>\n<tr>\n<td width=\"134\">T\/C<\/td>\n<td width=\"111\">43<\/td>\n<td width=\"378\">Cre\u0219terea riscului de depozitare a gr\u0103similor \u00een jurul organelor<\/td>\n<\/tr>\n<tr>\n<td width=\"134\">T\/T<\/td>\n<td width=\"111\">39<\/td>\n<td width=\"378\">\u2013<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&nbsp;<\/p>\n<p><strong>PPARG (rs1801382) <\/strong><\/p>\n<p>PPARG (Peroxisome proliferator-activated receptor gamma) este un membru al superfamiliei de receptori nucleari activa\u021bi de inductori ai prolifer\u0103rii peroxizomilor ce este localizat predominant \u00een adipocite. Odat\u0103 activat de c\u0103tre ligand, PPARG se leag\u0103 de o secven\u021b\u0103 specific\u0103 din structura ADN-ului \u0219i moduleaz\u0103 transcrip\u021bia genelor sale \u021bint\u0103, printre care se num\u0103r\u0103 gena ce codific\u0103 acyl-CoA oxidaza implicat\u0103 \u00een beta-oxidarea peroxizomal\u0103 a acizilor gra\u0219i. PPARG intervine \u00een diferen\u021bierea adipocitelor, reglarea sensibilit\u0103\u021bii la insulin\u0103 \u0219i lipogenez\u0103.<\/p>\n<p>Consumul unei diete bogate \u00een gr\u0103simi determin\u0103 hipertrofia adipocitelor sub influen\u021ba PPARG, iar celulele adipoase vor secreta factori de rezisten\u021b\u0103 la insulin\u0103, cum ar fi TNFa, rezistin, precum \u0219i acizi gra\u0219i liberi (14,15).<\/p>\n<p>Polimorfismul PPARG rs1801282 C&gt;G determin\u0103 sinteza unei proteine cu activitate redus\u0103 prin substitu\u021bia prolinei (Pro) cu alanina (Ala) \u00een pozi\u021bia 12 (Pro12Ala) \u0219i se presupune c\u0103 ar avea un efect protector \u00een ceea prive\u0219te dezvoltarea diabetului. Cu toate acestea,\u00a0 alela G minor\u0103 a fost asociat\u0103 cu obezitatea \u00een diverse popula\u021bii, \u00een prezen\u021ba unei diete bogate \u00een gr\u0103simi saturate.\u00a0 Subiec\u021bii supraponderali \u0219i obezi care prezint\u0103 polimorfismul PPARG rs1801282 C&gt;G pot beneficia de o diet\u0103 hipocaloric\u0103, cu un con\u021binut redus de gr\u0103simi, moderat de carbohidra\u021bi \u0219i proteine (6).<\/p>\n<div>\n<table class=\"wp-block-table w-100\">\n<tbody>\n<tr>\n<td width=\"119\">Genotip PPARG<\/td>\n<td width=\"106\">Frecven\u021b\u0103 (%)<\/td>\n<td width=\"391\">Efecte<\/td>\n<\/tr>\n<tr>\n<td width=\"119\">C\/C<\/td>\n<td width=\"106\">86<\/td>\n<td width=\"391\">Predispozi\u021bia genetic\u0103 la obezitate (OR: 1.38)<\/td>\n<\/tr>\n<tr>\n<td width=\"119\">C\/G<\/td>\n<td width=\"106\">12<\/td>\n<td width=\"391\">Efect Yo-Yo puternic&nbsp;<\/p>\n<p>Cre\u0219terea riscului de depozitare a gr\u0103similor \u00een jurul organelor<\/p>\n<p>Pierderea \u00een greutate se poate face eficient prin diet\u0103 hipocaloric\u0103<\/p>\n<p>Predispozi\u021bia genetic\u0103 la obezitate (OR: 1.19)<\/p>\n<p>R\u0103spuns mai bun la activitatea fizic\u0103<\/td>\n<\/tr>\n<tr>\n<td width=\"119\">G\/G<\/td>\n<td width=\"106\">2<\/td>\n<td width=\"391\">Efect Yo-Yo puternic&nbsp;<\/p>\n<p>Cre\u0219terea riscului de depozitare a gr\u0103similor \u00een jurul organelor<\/p>\n<p>Pierderea \u00een greutate se poate face eficient prin diet\u0103 hipocaloric\u0103<\/p>\n<p>R\u0103spuns mai bun la activitatea fizic\u0103<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&nbsp;<\/p>\n<p><strong>ADRB2<\/strong><strong> (rs1042713), ADRB2 (rs1042714), ADRB3 (rs4994)<\/strong><\/p>\n<p>Genele ADRB2 \u0219i ADRB3 codific\u0103 receptorii adrenergici \u03b22 \u0219i \u03b23. Ace\u0219tia fac parte din sistemul adrenergic care stimuleaz\u0103 mobilizarea lipidelor din \u021besutul adipos prin ac\u021biunea catecolaminelor (epinefrina \u0219i norepinefrina).<\/p>\n<p>ADRB2 este un receptor cuplat cu proteina G larg distribuit \u00een organism \u0219i localizat pe adipocite. Sub influen\u021ba catecolaminelor moduleaz\u0103 lipoliza \u0219i lipogeneza.<\/p>\n<p>Polimorfismele Arg16Gly (285A&gt;G, rs1042713) \u0219i Gln27Glu (318C&gt;G, rs1042714) din gena ADRB2 au fost asociate cu dezvoltarea excesului ponderal, hipertensiunii, sindromului metabolic, exacerb\u0103rilor astmului. Modific\u0103rile secven\u021bei de aminoacizi de la capatul N-terminal extracelular al receptorului sunt asociate cu alterarea lipolizei, modific\u0103ri \u00een reglarea metabolismului cardiovascular, precum \u0219i sc\u0103derea func\u021biei pulmonare \u0219i a r\u0103spunsul bronhodilatator la terapia cu beta-agoni\u0219ti. Pacien\u021bii purt\u0103tori ai alelei G pot beneficia de o diet\u0103 hipocaloric\u0103 combinat\u0103 cu un program de exerci\u021bii fizice (6,16) .<\/p>\n<p>Receptorul ADRB3 este localizat pe suprafa\u021ba celulelor adipoase (albe sau brune); promoveaz\u0103 lipoliza \u0219i termogeneza prin eliberarea noradrenalinei din nervii simpatici stimula\u021bi de temperaturi sc\u0103zute sau consumul alimentar.<\/p>\n<p>Unul dintre polimorfismele cel mai des investigate ale genei ADRB3 este p.Trp64Arg (c. T387C, rs4994). Mai multe studii au aratat ca este asociat cu o rat\u0103 metabolic\u0103 mai mic\u0103 \u00een repaus, obezitate abdominal\u0103, cre\u0219tere \u00een greutate \u0219i dificultate de a pierde kilogramele acumulate (6,16).<\/p>\n<div>\n<table class=\"wp-block-table w-100\">\n<tbody>\n<tr>\n<td width=\"134\">Genotip ADRB3<\/td>\n<td width=\"119\">Frecven\u021b\u0103 (%)<\/td>\n<td width=\"363\">Efecte<\/td>\n<\/tr>\n<tr>\n<td width=\"134\">T\/T<\/td>\n<td width=\"119\">83<\/td>\n<td width=\"363\">Pierderea \u00een greutate se poate face eficient prin activit\u0103\u021bi fizice<\/td>\n<\/tr>\n<tr>\n<td width=\"134\">T\/C<\/td>\n<td width=\"119\">16<\/td>\n<td width=\"363\">\u2013<\/td>\n<\/tr>\n<tr>\n<td width=\"134\">C\/C<\/td>\n<td width=\"119\">1<\/td>\n<td width=\"363\">\u2013<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&nbsp;<\/p>\n<div>\n<table class=\"wp-block-table w-100\">\n<tbody>\n<tr>\n<td width=\"127\">Genotip ADRB2 \u00a0rs1042713<\/td>\n<td width=\"126\">Frecven\u021b\u0103 (%)<\/td>\n<td width=\"363\">Efecte<\/td>\n<\/tr>\n<tr>\n<td width=\"127\">A\/A<\/td>\n<td width=\"126\">22<\/td>\n<td width=\"363\"><\/td>\n<\/tr>\n<tr>\n<td width=\"127\">A\/G<\/td>\n<td width=\"126\">51<\/td>\n<td width=\"363\">Efect Yo-Yo puternic<\/td>\n<\/tr>\n<tr>\n<td width=\"127\">G\/G<\/td>\n<td width=\"126\">27<\/td>\n<td width=\"363\">Efect Yo-Yo puternic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&nbsp;<\/p>\n<div>\n<table class=\"wp-block-table w-100\" width=\"617\">\n<tbody>\n<tr>\n<td width=\"133\">Genotip ADRB2\u00a0\u00a0 rs1042714<\/td>\n<td width=\"121\">Frecven\u021b\u0103 (%)<\/td>\n<td width=\"363\">Efect<\/td>\n<\/tr>\n<tr>\n<td width=\"133\">C\/C<\/td>\n<td width=\"121\">42<\/td>\n<td width=\"363\">\u2013<\/td>\n<\/tr>\n<tr>\n<td width=\"133\">C\/G<\/td>\n<td width=\"121\">51<\/td>\n<td width=\"363\">Cre\u0219terea sensibilit\u0103\u021bii la carbohidra\u021bi&nbsp;<\/p>\n<p>Efect Yo-Yo puternic<\/p>\n<p>Cre\u0219terea riscului de depozitare a gr\u0103similor \u00een jurul organelor<\/p>\n<p>Cre\u0219terea pierderii masei musculare \u00een cazul dietei hipocalorice<\/p>\n<p>Pierderea \u00een greutate se poate face eficient prin diet\u0103 hipocaloric\u0103<\/td>\n<\/tr>\n<tr>\n<td width=\"133\">G\/G<\/td>\n<td width=\"121\">7<\/td>\n<td width=\"363\">Cre\u0219terea sensibilit\u0103\u021bii la carbohidra\u021bi&nbsp;<\/p>\n<p>Efect Yo-Yo puternic<\/p>\n<p>Cre\u0219terea riscului de depozitare a gr\u0103similor \u00een jurul organelor<\/p>\n<p>Cre\u0219terea pierderii masei musculare \u00een cazul dietei hipocalorice<\/p>\n<p>Pierderea \u00een greutate se poate face eficient prin diet\u0103 hipocaloric\u0103<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>&nbsp;<\/p>\n<p><strong>Specimen recoltat<\/strong>: saliv\u0103 (kit-ul de recoltare este furnizat de laborator) (17).<\/p>\n<p>&nbsp;<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-31035 size-full aligncenter\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2018\/07\/1.png\" alt=\"Testare genetica pentru controlul greutatii (Weight Sensor) - Synevo\" width=\"641\" height=\"86\" \/><\/p>\n<p>&nbsp;<\/p>\n<p><strong>V\u0103 rug\u0103m s\u0103 nu m\u00e2nca\u021bi, nu be\u021bi, nu cl\u0103ti\u021bi gura si nu v\u0103 sp\u0103la\u021bi pe din\u021bi timp de cel pu\u021bin 30 de minute \u00eenainte de recoltare.<\/strong><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<h2><strong>Pregatire pacient \u00eenainte de recoltare<\/strong><\/h2>\n<p><img decoding=\"async\" class=\"alignnone wp-image-761594\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2020\/05\/1.png\" alt=\"Testare genetica pentru controlul greutatii (Weight Sensor) - Synevo\" width=\"125\" height=\"104\" \/>\u00a0 1. Masa\u021bi-v\u0103 obrajii ferm timp de 10 secunde pentru a permite desprinderea unei cantit\u0103\u021bi suficiente de celule de pe mucoasa cavit\u0103\u021bii bucale<\/p>\n<p><img decoding=\"async\" class=\"alignnone wp-image-761596\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2020\/05\/2.png\" alt=\"Testare genetica pentru controlul greutatii (Weight Sensor) - Synevo\" width=\"89\" height=\"107\" \/>\u00a0 \u00a0 \u00a0 \u00a02. Plimba\u021bi-v\u0103 limba de c\u0103teva ori pe interiorul obrajilor.<\/p>\n<p><strong>Pregatire materiale \u00eenainte de recoltare<\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-761597\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2020\/05\/3.png\" alt=\"Testare genetica pentru controlul greutatii (Weight Sensor) - Synevo\" width=\"91\" height=\"112\" \/>\u00a0 \u00a0 \u00a0 \u00a03. Deschide\u021bi eprubeta\/ tubul de recoltare \u0219i fixa\u021bi p\u00e2lnia la orificiul de deschidere a acesteia.<br \/>\n<strong>Aten\u021bie:<\/strong> NU arunca\u021bi capacul eprubetei\/ tubului de recoltare.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Recoltare<\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-761600\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2020\/05\/4.png\" alt=\"Testare genetica pentru controlul greutatii (Weight Sensor) - Synevo\" width=\"111\" height=\"109\" \/>\u00a0 \u00a0 4. Deschide\u021bi flaconul cu ap\u0103 \u0219i cl\u0103ti\u021bi-v\u0103 gura cu con\u021binutul acestuia timp de 10 secunde.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-761601\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2020\/05\/5.png\" alt=\"Testare genetica pentru controlul greutatii (Weight Sensor) - Synevo\" width=\"115\" height=\"111\" \/>\u00a0 \u00a0 5. Scuipa\u021bi lichidul \u00een eprubet\u0103 prin intermediul p\u00e2lniei.<\/p>\n<p><strong>Finalizarea procedurii<\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-761602\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2020\/05\/6.png\" alt=\"Testare genetica pentru controlul greutatii (Weight Sensor) - Synevo\" width=\"102\" height=\"107\" \/>\u00a0 \u00a0 6. \u00cenchide\u021bi eprubeta\/ tubul colector folosind capacul acesteia\/acestuia.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-761603\" src=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2020\/05\/7.png\" alt=\"Testare genetica pentru controlul greutatii (Weight Sensor) - Synevo\" width=\"92\" height=\"120\" \/>\u00a0 \u00a0 \u00a0 7. Introduce\u021bi eprubeta\/ tubul colector \u00een punga de transport a probei<\/p>\n<p>8. Sigila\u021bi punga.<br \/>\n9. Proba se pastreaza la temperatura camerei pana la predare catre laborator. Are stabilitate 7 zile.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Metod\u0103 <\/strong>\u2013 Real-time PCR (17).<\/p>\n<h2><strong>Raportarea \u0219i interpretarea rezultatelor<\/strong><\/h2>\n<p>Buletinul de analize va contine urm\u0103toarele informatii:<\/p>\n<ul>\n<li>Analiza genetic\u0103 a 8 polimorfisme implicate \u00een obezitate<\/li>\n<li>Factorii care contribuie predominant la obezitate (gr\u0103simi sau carbohidra\u021bi)<\/li>\n<li>Program de nutri\u021bie \u0219i exerci\u021bii fizice personalizate profilului genetic<\/li>\n<li>Raport ce contine peste 1000 alimente evaluate pe baza profilului genetic al pacientului<\/li>\n<li>Program de pierdere \u00een greutate<\/li>\n<li>Propuneri de meniuri zilnice personalizate in functie de profilul genetic<\/li>\n<li>Plan de diet\u0103 cu portalul DNAnutriControl (17).<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Puteti vizualiza un exemplu de rezultat <a href=\"https:\/\/www.synevo.ro\/wp-content\/uploads\/2020\/06\/weight.sensor.pdf\" data-wpel-link=\"internal\">aici<\/a><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Referin\u021be<\/strong><\/h2>\n<ol>\n<li>Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of Obesity Among Adults and Youth: United States 2011-2014. NCHS Data Brief., No129, November 2015. Ref Type: Internet Communication. <a href=\"https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db219.pdf\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db219.pdf<\/a>.<\/li>\n<li>World Health Organization. Obesity and overweight. Fact sheet (reviewed February 2018). Ref Type: Internet Communication. <a href=\"https:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\" target=\"_blank\" rel=\"noopener nofollow external noreferrer\" data-wpel-link=\"external\">https:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en<\/a>.<\/li>\n<li>Popa S, Mo\u021ba M, Popa A, Mo\u021ba E, Serafinceanu C, Guja C, Catrinoiu D, H\u00e2ncu N, Lichiardopol R, Bala C, Popa A, Roman G, Radulian G, Timar R, Mihai B. Prevalence of overweight\/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study. J Endocrinol Invest. 2016 Sep;39(9):1045-53.<\/li>\n<li>Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002 Dec;10 Suppl 2:97S-104S.<\/li>\n<li>Gregori D, Foltran F, Verduci E, Ballali S, Franchin L, Ghidina M, Halpern GM, Giovannini M. A genetic perspective on nutritional profiles: do we still need them? J Nutrigenet Nutrigenomics. 2011;4(1):25-35.<\/li>\n<li>Coletta A and Kreider RB. Genetic Profiling for Weight Loss: Potential Candidate Genes. Bioenergetics 2015, 4:2 DOI: 10.4172\/2167-7662.1000126<\/li>\n<li>Qiu CJ, Ye XZ, Yu XJ, Peng XR, Li TH. Association between FABP2 Ala54Thr polymorphisms and type 2 diabetes mellitus risk: a HuGE Review and Meta-Analysis. J Cell Mol Med. 2014 Dec;18(12):2530-5.<\/li>\n<li>Han TK. Effects Ala54Thr polymorphism of FABP2 on obesity index and biochemical variable in response to a aerobic exercise training J Exerc Nutrition Biochem. 2013 Dec;17(4):209-1.<\/li>\n<li>Choquet H, Meyre D. Genetics of Obesity: What have we Learned? Curr Genomics. 2011 May;12(3):169-79.<\/li>\n<li>Castellini G, Franzago M, Bagnoli S, Lelli L, Balsamo M, Mancini M, Nacmias B, Ricca V, Sorbi S, Antonucci I, Stuppia L, Stanghellini G. Fat mass and obesity-associated gene (FTO) is associated to eating disorders susceptibility and moderates the expression of psychopathological traits. PLoS One. 2017 Mar 10;12(3): e0173560.<\/li>\n<li>Zaki ME, Amr KS, Abdel-Hamid M. APOA2 Polymorphism in Relation to Obesity and Lipid Metabolism. Cholesterol. 2013; 2013:289481.<\/li>\n<li>Remaley AT. Apolipoprotein A-II: Still second fiddle in HDL metabolism? Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):166-7.<\/li>\n<li>Forte TM, Sharma V, Ryan RO. Apolipoprotein A-V gene therapy for disease prevention \/ treatment: a critical analysis. J Biomed Res. 2016 Mar;30(2):88-93.<\/li>\n<li>Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S. PPAR\u03b3 and the global map of adipogenesis and beyond. Trends Endocrinol Metab. 2014 Jun;25(6):293-302.<\/li>\n<li>Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, Hunter DJ. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet. 2003 Nov 15;12(22):2923-9.<\/li>\n<li>Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation. 2005 Jun 28;111(25):3429-34.<\/li>\n<li>Laborator Synevo. Referin\u021bele specifice tehnologiei de lucru utilizate 2018. Ref Type: Catalog.<\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"<p>Informa\u021bii generale \u2013 Testare genetic\u0103 pentru controlul greut\u0103\u021bii (test de nutrigenetica) \u2013 (Weight Sensor) Potrivit Centrului pentru Controlul \u0219i Prevenirea Bolilor (CDC), \u00een ultimele dou\u0103 decenii s-a \u00eenregistrat o cre\u0219tere constant\u0103 a ratei obezit\u0103\u021bii \u00een Statele Unite \u00een r\u00e2ndul adul\u021bilor de la 19,4% \u00een 1997 la 24.5% \u00een 2004, 26.6% \u00een 2007, 33.8% \u00een 2008, [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[45,98],"product_tag":[],"class_list":["post-252","product","type-product","status-publish","product_cat-teste-de-biologie-moleculara","product_cat-teste-de-nutrigenetica","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"_links":{"self":[{"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product\/252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:attachment":[{"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/media?parent=252"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product_brand?post=252"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product_cat?post=252"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/analizesanocare.ro\/en\/wp-json\/wp\/v2\/product_tag?post=252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}